Dudley Thomas E, Gioe Terence J, Sinner Penny, Mehle Susan
Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN, USA.
Clin Orthop Relat Res. 2008 Jul;466(7):1666-70. doi: 10.1007/s11999-008-0279-3. Epub 2008 May 9.
Perceptions of the difficulty and outcome of unicompartmental knee arthroplasty revision (rev-UKA) vary. We analyzed differences in the complexity, cost, and survival of rev-UKAs compared with revision TKAs (rev-TKA). One hundred eighty knee arthroplasty revisions (68 rev-UKAs/112 rev-TKAs), defined as a minimum of tibial or femoral component revision, were identified from a community joint registry of 7587 knee implants performed between 1991 and 2005. Four of 68 rev-UKAs (5.9%) were revised a second time, whereas seven of 112 rev-TKAs (6.3%) were rerevised. Rev-TKA was predictably more complex than rev-UKA based on the proxies of operative time, use of modular augmentation and stems, and polyethylene liner thickness. Thirty-nine of 68 rev-UKAs (57%) had no form of augmentation and were revised as primary TKAs. There were more rev-TKAs than rev-UKAs with an implant cost greater than $5200 (42% versus 12%) and hospital charges greater than $33,000 (48% versus 25%). We found no difference in survival between the groups. Although rev-UKAs had less surgical complexity and bone loss at the time of revision compared with rev-TKAs, we were unable to show improved survival of rev-UKAs compared with rev-TKAs. Rev-UKAs were associated with lower implant costs and hospital charges compared with rev-TKAs.
Level II, prognostic study.
单髁膝关节置换术翻修(rev-UKA)的难度和结果的认知存在差异。我们分析了与全膝关节置换术翻修(rev-TKA)相比,rev-UKA在复杂性、成本和生存率方面的差异。从1991年至2005年期间进行的7587例膝关节植入物的社区关节登记处中,确定了180例膝关节置换术翻修病例(68例rev-UKA/112例rev-TKA),定义为至少进行胫骨或股骨组件翻修。68例rev-UKA中有4例(5.9%)进行了二次翻修,而112例rev-TKA中有7例(6.3%)进行了再次翻修。基于手术时间、模块化增强和柄的使用以及聚乙烯衬垫厚度等指标,rev-TKA比rev-UKA更复杂是可预测的。68例rev-UKA中有39例(57%)没有任何形式的增强,并且作为初次全膝关节置换术进行了翻修。植入物成本高于5200美元的rev-TKA比rev-UKA更多(42%对12%),医院收费高于33000美元的情况也是如此(48%对25%)。我们发现两组之间的生存率没有差异。尽管与rev-TKA相比,rev-UKA在翻修时手术复杂性和骨丢失较少,但我们无法证明rev-UKA与rev-TKA相比生存率有所提高。与rev-TKA相比,rev-UKA的植入物成本和医院收费较低。
二级,预后研究。